Latest Conference Coverage

Improving MS Management Through Early Intervention and Precision Medicine: Emilio Portaccio, MD

The professor of neurology at University of Florence talked about how early intervention, broader assessment tools, and personalized approaches are essential for effectively managing multiple sclerosis. [WATCH TIME: 4 minutes]

NeuroVoices: Jacqueline A. French, MD, on Leveraging Neurostimulators to Advance Epilepsy Drug Development

The professor of neurology at NYU Grossman School of Medicine talked about using responsive neurostimulators to seek shortened drug evaluation timelines and enhance epilepsy treatment.

Bridging Clinical Signs and Biological Evidence to Transform MS Diagnosis: Marcello Moccia, MD, PhD

At ECTRIMS 2024, the assistant professor at the University of Naples the latest multiple sclerosis diagnostic criteria, which emphasized a shift toward biologically based diagnoses. [WATCH TIME: 4 minutes]

Navigating the Decision to Treat Multiple Sclerosis Early Versus Later: Mikael Cohen, MD

At the 2024 ECTRIMS Congress, the neurologist at the University Hospital Center of Nice talked about how the decision to treat patients at risk of MS is highly individualized. [WATCH TIME: 3 minutes]

Improving MS Diagnosis Through Biology and Early Detection: Wallace Brownlee, MBChB, PhD, FRACP

At ECTRIMS 2024, the consultant neurologist at Queen's Square MS Center in London talked about the evolving McDonald criteria to define multiple sclerosis biologically. [WATCH TIME: 5 minutes]

The Philosophy and Future of the DAAE Score in Multiple Sclerosis Care: Tom Fuchs, MD, PhD

At ECTRIMS 2024, the postdoctoral researcher at Amsterdam University Medical Center talked about an evolving tool developed to predict disease progression in multiple sclerosis. [WATCH TIME: 7 minutes]

Optimizing MS Treatment With Timely Interventions and Individualized Care: Valentin Krüger, MD

The neurology resident at the University Hospital Frankfurt in Germany talked about the importance of initiating treatment early for patients with multiple sclerosis to improve long-term outcomes. [WATCH TIME: 6 minutes]

Rethinking Treatment Strategies in NMOSD Based on Safety Failures and Emerging Therapies: Shamik Bhattacharyya, MD

The associate professor of neurology at Harvard Medical School talked about reconsidering therapy switches for NMOSD, incorporating safety failures like recurrent infections, and prioritizing real-world studies to validate findings. [WATCH TIME: 5 minutes]

Clinical Program and Next Steps for Zorevunersen as Potential Disease-Modifying Treatment for Dravet: Barry Ticho, MD, PhD

The chief medical officer at Stoke Therapeutics discussed recent developments for zorevunersen, including the significance of breakthrough therapy designation and its plan for a phase 3 trial. [WATCH TIME: 5 minutes]

Optimizing Epilepsy Treatments: Stiripentol’s Role in Dravet Syndrome

James Wheless, MD, FAAP, FAAN, FAES, Le Bonheur Chair in Pediatric Neurology at the University of Tennessee Health Science Center, shared insights on his presentation from AES 2024, focusing on stiripentol, an FDA-approved treatment for Dravet syndrome.

Advancing Understanding of the Preclinical Phase of Multiple Sclerosis: Christina J. Azevedo, MD

At the 2024 ECTRIMS Congress, the associate professor of clinical neurology at Keck School of Medicine of USC talked about recent research that highlights the preclinical phase of multiple sclerosis. [WATCH TIME: 9 minutes]

Stoke Announces Phase 3 EMPEROR Registrational Study for Zorevunersen in Dravet Syndrome

The global Phase 3 trial aims to enroll ~150 patients with Dravet syndrome who have SCN1A variants, assessing zorevunersen's impact on seizure frequency, behavior, cognition, and safety over 60 weeks, with results expected by 2027.

NeuroVoices: Fred Lublin, MD, on Shifting From Phenotypes to Spectrum-Based Perspectives to Advance Multiple Sclerosis Care

The director of the Corinne Goldsmith Dickinson Center for MS at Mount Sinai talked about how modern advances research have helped transition the understanding of multiple sclerosis from fixed phenotypes to a dynamic spectrum.

Raising Awareness and Advancing Management for Developmental Epileptic Encephalopathy With Spike Wave Activation

Lekha Rao, MD, an epileptologist at UCLA Health, discussed the challenges in diagnosing D/EE-SWAS, the importance of early EEG, and the need for greater awareness around this rare and complex epileptic condition.

Overlapping Diagnoses and the Advancement of MS Detection in NMDARE: Joseph Kuchling, MD

The postdoctoral research assistant at Charité University Berlin discussed advances in diagnostic criteria and 7-Tesla MRI imaging, highlighting a previously overlooked overlap between anti-N-methyl-D-aspartate receptor encephalitis and multiple sclerosis. [WATCH TIME: 5 minutes]

Reducing the Burden: Proactive Care Strategies for Lennox-Gastaut Syndrome

Babitha Haridas, MD, MBBS, a pediatric epileptologist at Johns Hopkins Medicine, discussed the complexities with managing status epilepticus in Lennox-Gastaut syndrome, focusing on the importance of identifying triggers early in their condition.

Evolving MS Diagnostics From Categorical Classifications to Biological Phenotyping: Fred Lublin, MD

The director of the Corinne Goldsmith Dickinson Center for MS at Mount Sinai talked about the shift in multiple sclerosis diagnostics from rigid classification systems to a dynamic, spectrum-based approach focused on biological phenotyping. [WATCH TIME: 5 minutes]

Defining Progression Independent of Relapsing Activity and Insights into Early Multiple Sclerosis Progression: Emilio Portaccio, MD

The professor of neurology at University of Florence talked about a study presented at ECTRIMS 2024 that validated definitions of progression independent of relapse activity in early relapsing MS. [WATCH TIME: 5 minutes]

Improving Access and Reducing Latency in Genetic Testing for Epilepsy: Julie Ziobro, MD, PhD; John Schreiber, MD

A duo of experts discussed the importance of addressing barriers such as provider comfort, access to genetic counselors, and insurance coverage to reduce diagnostic latency and standardize genetic testing for epilepsy. [WATCH TIME: 5 minutes]

Studying Nerve Cell Therapy NRTX-1001 to Treat Mesial Temporal Lobe Epilepsy: Jonathan Parker, MD, PhD

The assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona discussed an ongoing early-stage study assessing the therapeutic potential of NRTX-1001 nerve cell therapy in drug-resistant unilateral mesial temporal lobe epilepsy. [WATCH TIME: 5 minutes]

Advancing Epilepsy Research Through Implementation Science and Biomarkers: Adam Numis, MD; Laura Kirkpatrick, MD

At AES 2024, a duo of pediatric epilepsy specialists discussed how implementation science, validated blood biomarkers, and cross-disciplinary collaboration are advancing epilepsy care and closing research gaps. [WATCH TIME: 3 minutes]

Transforming Neurological Care for Children Through Education, Support, and Collaboration: Jessica Nickrand, PhD; Allyson Eyermann

A duo from Child Neurology Foundation discussed advancing care, providing education for all stakeholders, and offering direct support to families, clinicians, and caregivers navigating neurological conditions for pediatric patients. [WATCH TIME: 5 minutes]

NeuroVoices: Barry Ticho, MD, PhD, on the Disease-Modifying Potential of STK-001 in Treating Dravet Syndrome

The chief medical officer at Stoke Therapeutics sat down at AES 2024 to discuss the promising data behind STK-001, an investigational antisense oligonucleotide in development for Dravet syndrome.

Novel Approach to Antiseizure Drug Development With Use of Long Episodes: Jacqueline A. French, MD

The professor of neurology at NYU Grossman School of Medicine discussed a pioneering study using long seizure episodes to optimize treatment devices and identify effective antiseizure drugs in epilepsy care. [WATCH TIME: 2 minutes]

Using the PERC Database to Gather Insights on Epilepsy Genetics: Julie Ziobro, MD, PhD; John Schreiber, MD

A duo of experts talked about 2 studies presented at AES 2024 that used the Pediatric Epilepsy Research Consortium genetics database to study factors influencing latency in genetic testing and drug-resistant epilepsy. [WATCH TIME: 5 minutes]

Addressing Disparities and Improving Care Through Pediatric Epilepsy Research: Adam Numis, MD; Laura Kirkpatrick, MD

At AES 2024, a duo of pediatric epilepsy specialists highlighted a Pediatric Epilepsy Research Consortium review on the need for standardized socio-demographic data and better follow-up for at-risk infants. [WATCH TIME: 5 minutes]

Insights From Child Neurology Foundation on Advancing Holistic Epilepsy Care: Jessica Nickrand, PhD; Allyson Eyermann

A duo from the Child Neurology Foundation discussed multidisciplinary collaboration, innovations in epilepsy care, and the importance of holistic, family-centric approaches to improving patient outcomes at AES 2024. [WATCH TIME: 5 minutes]

Advancing Epilepsy Treatment With Novel Approaches and Predictive Technologies: Jacqueline A. French, MD

The professor of neurology at NYU Grossman School of Medicine discussed how innovative startups are using proof-of-concept studies and devices like responsive neurostimulators to improve patient outcomes. [WATCH TIME: 6 minutes]

Exploring Surgical Advances for Drug-Resistant Epilepsy in Children After Neonatal Stroke

Epileptologists Siddharth Jain, MD, MBBS, and Cemal Karakas, MD, provided commentary on a poster presentation at AES 2024 focusing on factors influencing seizure freedom in children who’ve experienced neonatal and perinatal arterial strokes.

Episode 130: The Promise Behind Cell Therapy in Epilepsy

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jonathon Parker, MD, PhD. [LISTEN TIME: 23 minutes]